JOURNAL OF IIMER May 2026 Dr Wenzhong Xiao of Harvard Medical School will present on a mouse model for reversing post-exertional malaise. If translatable to humans, this work could open a direct path towards therapeutic intervention for one of ME's most debilitating and defining features. Dr Steve Gardner, CEO of PrecisionLife, will address the question of GLP-1 receptor agonists for ME and long COVID - drugs that have transformed treatment of obesity and type 2 diabetes - examining the evidence, the hope and the potential risks of applying them to post-viral conditions. IIMEC18 International ME Conference Day – Colloquium Day 3 The day opens with an address from Dr Hans Kluge, WHO Regional Director for Europe. As members of the European ME Alliance we have been working with our European partners on several campaigns relating to WHO Europe initiatives. This will be the second time that WHO has contributed a message to the events. BRMEC15 Session 9: Therapeutics The Therapeutics session marks a pivotal point in the three-day programme - moving from the science of mechanisms towards the science of intervention. After two days of presentations on the biological underpinnings of ME, this session addresses what can now be done: clinical trial infrastructure, cognitive rehabilitation, mitochondrial intervention, and the use of digital and wearable technology to capture the complexity of ME in research and trials. Moderated by Professor Andrew Wilson, University of East Anglia, UK The final day of BRMEC15 merges with the 18th International ME Conference (IIMEC18), bringing researchers, clinicians and patients together for the first time in the programme. Professor Wilson also presents in his own right, on the development of a platform for clinical trials in ME - infrastructure that is essential if the growing body of mechanistic findings in ME research is to be translated into tested and validated treatments. Dr Vicky Whittemore is a Programme Director in the Division of Neuroscience at the National Institutes of Health, where she has played a central role in coordinating and advancing the NIH's investment in ME research. With a background spanning epilepsy, neurological disorders and translational neuroscience, she has served on key advisory and working groups shaping the direction of ME research at a national and international level, including the NIH P2P CFS Committee and the National Academy of Medicine's ME/CFS case definition working group. Her contribution to this session reflects the importance of sustained institutional commitment to the Invest in ME Research Page 30 of 35
32 Publizr Home